Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed newly diagnosed, localized adenocarcinoma of the prostate, meeting any of the following criteria:~  * Clinical stage T2a, T2b, T2c, or T3 disease (any grade or PSA)~ * Gleason score 7 (4+3 only) or ≥ 8 (any stage or PSA)~ * Serum PSA ≥ 10 ng/dL (any grade or stage)~ * Any stage, PSA, or Gleason score AND ≥ 35% chance of biochemical failure at 5 years based on Kattan's nomogram~* Recommended for radical prostatectomy~* Normal testosterone level~* No pure neuroendocrine or small cell prostate cancer~* No metastatic disease by CT scan, MRI, bone scan, or X-ray~* No clinical evidence of CNS metastases~PATIENT CHARACTERISTICS:~Inclusion criteria:~* ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%~* ANC ≥ 1,500/μL~* Platelet count ≥ 100,000/μL~* Hemoglobin ≥ 8 g/dL~* AST and ALT ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* Creatinine ≤ 1.5 times ULN~* PT/PTT normal (no anticoagulants)~* No active unresolved infection~* No known HIV positivity~* Fertile patients must use effective contraception during and for 6 months after completion of study therapy~Exclusion criteria:~* Known hypersensitivity to everolimus or other rapamycins (e.g., sirolimus or temsirolimus) or to its excipients~* Gastrointestinal (GI) disease, condition, or symptoms that may significantly impair GI function and alter the absorption of everolimus, including any of the following:~  * Ulcerative disease~ * Uncontrolled nausea~ * Vomiting~ * Diarrhea~ * Malabsorption syndrome~* Other active malignancy or malignancy at ≥ 30% risk for relapse after completion of therapy, except nonmelanoma skin cancer~* Uncontrolled concurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection (e.g., bacterial, viral or fungal)~ * Severely impaired lung function~ * Uncontrolled diabetes (fasting serum glucose \> 1.5 times ULN)~ * Liver disease (e.g., cirrhosis, chronic active hepatitis, or chronic persistent hepatitis)~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~* Psychiatric illness or social situation that would limit study compliance~* Any underlying medical condition which, in the principal investigator's opinion, will make the administration of everolimus hazardous OR obscure the interpretation of adverse events~PRIOR CONCURRENT THERAPY:~* More than 4 weeks since major surgery~* More than 3 months since finasteride~* No prior or concurrent radiotherapy to the prostate gland or pelvis~* No prior hormones (e.g., luteinizing hormone-releasing hormone \[LHRH\] agonists, LHRH antagonists, or antiandrogens \[e.g., bicalutamide, flutamide, or nilutamide\]) and/or PC-SPES (or PC-x product) or estrogen-containing nutraceuticals~* No prior rapamycin mTOR inhibitor~* No prior small bowel resection that may significantly impair GI function and alter the absorption of everolimus~* No prior or concurrent immunotherapy, chemotherapy, or other investigational therapy for prostate cancer~* No other concurrent investigational or commercial agents~* No other concurrent anticancer agents~* No concurrent, chronic treatment with systemic steroids (except inhaled or topical steroids) or another immunosuppressive agent~* No concurrent live vaccines~* No concurrent strong inhibitors or inducers of the isoenzyme CYP3A administered as systemic therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Low-dose Everolimus Cohort (Type: EXPERIMENTAL): 5mg Everolimus daily continuously for 8 weeks and conventional surgery
- High-dose Everolimus Cohort (Type: ACTIVE_COMPARATOR): 10mg Everolimus daily continuously for 8 weeks and conventional surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues